The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Jamshedpur/Ranchi: Ever wonder why non-alcoholic fatty liver disease (NAFLD) is on the rise not only among adults but also ...

It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas.

Feeling overwhelmed by exams, pressure, or expectations? Let Sadhguru's wisdom guide you through. These 8 quotes will calm ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Big picture: We expect Pfizer to continue to prioritize obesity as a therapeutic area in its pipeline, either with external deals or additional internal advancement. Pfizer did achieve its goal of ...

Teachers have a profound impact on society, so it’s no wonder that history’s great thinkers sing the praises of educators with eloquent teacher quotes. 19. “The greatest sign of success for ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

The understanding of obesity in India is shifting, with growing recognition that it's a complex disease requiring medical management, not just a lifestyle issue, experts said during a discussion ...

DOWN. ROYALE AND TODD, BACK TO YOU. ALL RIGHT, COREY, THANK YOU SO MUCH. NEW ON SEVEN. CHILDHOOD OBESITY RATES ARE DROPPING IN NEW MEXICO. BUT THEY’RE STILL HIGHER THAN THE NATIONAL AVERAGE.